Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0IONHY |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Humanized anti-CD47 IgG1 mAb |
|||||
| Synonyms |
Humanized anti-CD47 IgG1 mAb
Click to Show/Hide
|
|||||
| Antigen Name | Leukocyte surface antigen CD47 (CD47) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SGN-CD47M [Phase 1 (terminated/withdrawn)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients (ECOG 0-1) must have specified metastatic solid tumors and measurable disease, with adequate contraception required. Key exclusions include prior CD47/SIRPalpha therapy, active CNS metastases, HIV/hepatitis infections, recent transfusions or immunosuppression, and cardiovascular events within 6 months. Life expectancy must exceed 12 weeks.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03957096 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 Study of SGN-CD47M in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
The study will assess safety parameters including adverse events and laboratory abnormalities over 24 months, with dose-limiting toxicities evaluated specifically within the first 28 days of treatment.
|
||||
| Other Endpoint |
Efficacy evaluations will include ORR, DOR, PFS and OS according to both RECIST v1.1 and iRECIST criteria, with assessments continuing for up to 4 years. Pharmacokinetic measurements (AUC, Cmax, Tmax, Ctrough) and immunogenicity (ADA) will be monitored for 24 months.
|
||||